Your browser doesn't support javascript.
loading
Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme.
Lebrett, Mikey B; Balata, Haval; Evison, Matthew; Colligan, Denis; Duerden, Rebecca; Elton, Peter; Greaves, Melanie; Howells, John; Irion, Klaus; Karunaratne, Devinda; Lyons, Judith; Mellor, Stuart; Myerscough, Amanda; Newton, Tom; Sharman, Anna; Smith, Elaine; Taylor, Ben; Taylor, Sarah; Walsham, Anna; Whittaker, James; Barber, Phil V; Tonge, Janet; Robbins, Hilary A; Booton, Richard; Crosbie, Philip A J.
Afiliação
  • Lebrett MB; Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK.
  • Balata H; Prevention and Early Detection Theme, NIHR Manchester Biomedical Research Centre, Manchester, UK.
  • Evison M; Division of Infection, Immunity and Respiratory Medicine, The University of Manchester, Manchester, UK.
  • Colligan D; Manchester Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Duerden R; Manchester Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Elton P; South Manchester Clinical Commissioning Group, Macmillan Cancer Improvement Partnership, Manchester, UK.
  • Greaves M; Manchester Health and Care Commissioning, Manchester, Manchester, UK.
  • Howells J; Manchester Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Irion K; Department of Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Karunaratne D; Greater Manchester and Eastern Cheshire Strategic Clinical Networks, Manchester, Manchester, UK.
  • Lyons J; Manchester Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Mellor S; Department of Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Myerscough A; Department of Radiology, Royal Preston Hospital, Preston, Lancashire, UK.
  • Newton T; Department of Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Sharman A; Department of Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Smith E; Manchester Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Taylor B; Department of Radiology, Royal Blackburn Hospital, Blackburn, UK.
  • Taylor S; South Manchester Clinical Commissioning Group, Macmillan Cancer Improvement Partnership, Manchester, UK.
  • Walsham A; Department of Radiology, Royal Blackburn Hospital, Blackburn, UK.
  • Whittaker J; Manchester Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Barber PV; Department of Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Tonge J; Manchester Thoracic Oncology Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Robbins HA; Department of Radiology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Booton R; Department of Radiology, Christie NHS Foundation Trust, Manchester, Manchester, UK.
  • Crosbie PAJ; South Manchester Clinical Commissioning Group, Macmillan Cancer Improvement Partnership, Manchester, UK.
Thorax ; 75(8): 661-668, 2020 08.
Article em En | MEDLINE | ID: mdl-32631933
ABSTRACT

INTRODUCTION:

Low-dose CT (LDCT) screening of high-risk smokers reduces lung cancer (LC) specific mortality. Determining screening eligibility using individualised risk may improve screening effectiveness and reduce harm. Here, we compare the performance of two risk prediction models (PLCOM2012 and Liverpool Lung Project model (LLPv2)) and National Lung Screening Trial (NLST) eligibility criteria in a community-based screening programme.

METHODS:

Ever-smokers aged 55-74, from deprived areas of Manchester, were invited to a Lung Health Check (LHC). Individuals at higher risk (PLCOM2012 score ≥1.51%) were offered annual LDCT screening over two rounds. LLPv2 score was calculated but not used for screening selection; ≥2.5% and ≥5% thresholds were used for analysis.

RESULTS:

PLCOM2012 ≥1.51% selected 56% (n=1429) of LHC attendees for screening. LLPv2 ≥2.5% also selected 56% (n=1430) whereas NLST (47%, n=1188) and LLPv2 ≥5% (33%, n=826) selected fewer. Over two screening rounds 62 individuals were diagnosed with LC; representing 87% (n=62/71) of 6-year incidence predicted by mean PLCOM2012 score (5.0%). 26% (n=16/62) of individuals with LC were not eligible for screening using LLPv2 ≥5%, 18% (n=11/62) with NLST criteria and 7% (n=5/62) with LLPv2 ≥2.5%. NLST eligible Manchester attendees had 2.5 times the LC detection rate than NLST participants after two annual screens (≈4.3% (n=51/1188) vs 1.7% (n=438/26 309); p<0.0001). Adverse measures of health, including airflow obstruction, respiratory symptoms and cardiovascular disease, were positively correlated with LC risk. Coronary artery calcification was predictive of LC (adjOR 2.50, 95% CI 1.11 to 5.64; p=0.028).

CONCLUSION:

Prospective comparisons of risk prediction tools are required to optimise screening selection in different settings. The PLCOM2012 model may underestimate risk in deprived UK populations; further research focused on model calibration is required.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Seleção de Pacientes / Detecção Precoce de Câncer / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Seleção de Pacientes / Detecção Precoce de Câncer / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article